Human C-reactive protein (CRP) has been implicated in the inflammatory responses associated with heart attacks and strokes. A small-molecule inhibitor of CRP limits myocardial infarction in rats and should facilitate mechanistic studies of cardiovascular disease.
This is a preview of subscription content, log in via an institution to check access.
Ann Thomson
References
Gabay, C. & Kushner, I. N. Engl. J. Med. 340, 448–454 (1999).
Ridker, P.M., Rifai, N., Rose, L., Buring, J.E. & Cook, N.R. N. Engl. J. Med. 347, 1557–1565 (2002).
Pepys, M.B. et al. Nature 440, 1217–1221 (2006).
Black, S., Kushner, I. & Samols, D. J. Biol. Chem. 279, 48487–48490 (2004).
Libby, P. & Ridker, P.M. Am. J. Med. 16 (suppl. 6A), 9S–16S (2004).
Chait, A., Han, C.Y., Oram, J.F. & Heinecke, J.W. J. Lipid Res. 46, 389–403 (2005).
Torzewski, J. Am. J. Pathol. 167, 923–925 (2005).
Saffitz, J.E. & Schwartz, C.J. Cardiol. Clin. 5, 21–30 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heinecke, J. Chemical knockout of C-reactive protein in cardiovascular disease. Nat Chem Biol 2, 300–301 (2006). https://doi.org/10.1038/nchembio0606-300
Issue Date:
DOI: https://doi.org/10.1038/nchembio0606-300
- Springer Nature America, Inc.
This article is cited by
-
CRP-Apherese bei akutem Myokardinfarkt bzw. COVID-19
Medizinische Klinik - Intensivmedizin und Notfallmedizin (2022)